Senores Pharmaceuticals Share Price
1428.20-2.20 (-0.15%)
+100.39% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 204% | 86% |
| - | - | 290% | 78% |
| - | - | - | 101% |
| 15% | 15% | 20% | 12% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
SENORES
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,899.9 | ₹456833 Cr | 37.77 | 12.07 | 62.82 | ₹11479 Cr |
| 9,150 | ₹245426 Cr | 83.91 | 34.04 | 128.41 | ₹2568 Cr |
| 4,830 | ₹187320 Cr | 85.89 | 16.72 | 97.06 | ₹2163 Cr |
| 1,126.9 | ₹113217 Cr | 25.09 | 9.42 | 62.53 | ₹5040 Cr |
| 1,379.6 | ₹112212 Cr | 33.29 | 9.77 | 57.87 | ₹3879 Cr |
| 1,844.8 | ₹101155 Cr | 92.52 | 6.8 | 29.25 | ₹889 Cr |
| 2,110 | ₹97626 Cr | 17.66 | 30.95 | 154.36 | ₹5333 Cr |
| 2,330.3 | ₹96859 Cr | 47.42 | 13.75 | 71.08 | ₹1913 Cr |
| 1,157.4 | ₹96406 Cr | 29.92 | 5.32 | 63.99 | ₹4196 Cr |
| 1,651 | ₹93614 Cr | 25.22 | 17.95 | 96.84 | ₹3505 Cr |
| 1,428.2 | ₹6597 Cr | 52.2 | 6.67 | 35.08 | ₹122 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹180 Cr | ₹175 Cr | ₹175 Cr | ₹162 Cr | ₹133 Cr | ₹114 Cr | ₹103 Cr | ₹101 Cr | ₹80 Cr | ₹102 Cr | ₹79 Cr |
| ₹3 Cr | ₹18 Cr | ₹4 Cr | ₹5 Cr | ₹9 Cr | ₹12 Cr | ₹5 Cr | ₹2 Cr | ₹48 L | ₹2 Cr | ₹80 L |
| ₹183 Cr | ₹193 Cr | ₹178 Cr | ₹167 Cr | ₹141 Cr | ₹126 Cr | ₹108 Cr | ₹102 Cr | ₹81 Cr | ₹104 Cr | ₹80 Cr |
| ₹136 Cr | ₹137 Cr | ₹128 Cr | ₹120 Cr | ₹110 Cr | ₹100 Cr | ₹82 Cr | ₹81 Cr | ₹63 Cr | ₹84 Cr | ₹67 Cr |
| ₹57 Cr | ₹65 Cr | ₹58 Cr | ₹55 Cr | ₹38 Cr | ₹31 Cr | ₹31 Cr | ₹25 Cr | ₹22 Cr | ₹24 Cr | ₹16 Cr |
| ₹7 Cr | ₹8 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr |
| ₹39 Cr | ₹47 Cr | ₹45 Cr | ₹41 Cr | ₹26 Cr | ₹21 Cr | ₹20 Cr | ₹16 Cr | ₹13 Cr | ₹18 Cr | ₹10 Cr |
| ₹30 Cr | ₹37 Cr | ₹34 Cr | ₹30 Cr | ₹21 Cr | ₹18 Cr | ₹16 Cr | ₹13 Cr | ₹11 Cr | ₹14 Cr | ₹7 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| — | — | — | — |
| ₹46 Cr | ₹31 Cr | ₹10 Cr | ₹9 Cr |
| ₹740 Cr | ₹174 Cr | ₹36 Cr | ₹28 Cr |
| ₹740 Cr | ₹174 Cr | ₹36 Cr | ₹28 Cr |
| ₹786 Cr | ₹204 Cr | ₹45 Cr | ₹37 Cr |
| ₹26 Cr | ₹27 Cr | ₹0 | ₹0 |
| ₹81 Cr | ₹28 Cr | ₹0 | ₹20,000 |
| ₹82 Cr | ₹106 Cr | ₹30 Cr | ₹12 Cr |
| -₹19 Cr | -₹15 Cr | ₹2 Cr | -₹45 L |
| ₹8 Cr | ₹8 Cr | ₹2 Cr | ₹41 L |
| ₹3 Cr | ₹1 Cr | ₹26 L | ₹5 L |
| ₹155 Cr | ₹128 Cr | ₹34 Cr | ₹12 Cr |
| — | — | — | — |
| ₹67 Cr | ₹113 Cr | ₹14 Cr | ₹7 Cr |
| ₹127 Cr | ₹94 Cr | ₹28 Cr | ₹62 L |
| ₹31 Cr | ₹32 Cr | ₹8 Cr | ₹2 Cr |
| ₹16 Cr | ₹8 Cr | ₹2 Cr | ₹14 L |
| ₹241 Cr | ₹248 Cr | ₹52 Cr | ₹10 Cr |
| ₹1208 Cr | ₹607 Cr | ₹131 Cr | ₹59 Cr |
| ₹21 Cr | ₹23 Cr | ₹8 Cr | ₹0 |
| ₹305 Cr | ₹248 Cr | ₹61 Cr | ₹14 Cr |
| — | — | — | — |
| ₹331 Cr | ₹249 Cr | ₹30 Cr | ₹8 Cr |
| ₹30 Cr | ₹13 Cr | ₹3 Cr | ₹1 Cr |
| ₹301 Cr | ₹235 Cr | ₹27 Cr | ₹7 Cr |
| ₹44 Cr | ₹18 Cr | ₹8 Cr | ₹35 L |
| ₹1 L | ₹1 L | ₹16 Cr | ₹15 Cr |
| ₹1 L | ₹1 L | ₹16 Cr | ₹15 Cr |
| ₹9 Cr | ₹4 Cr | ₹1 Cr | ₹1 Cr |
| ₹4 Cr | ₹19 Cr | ₹40 L | ₹14 L |
| ₹486 Cr | ₹356 Cr | ₹80 Cr | ₹32 Cr |
| — | — | — | — |
| ₹57 Cr | ₹37 Cr | ₹3 Cr | ₹3 Cr |
| ₹124 Cr | ₹112 Cr | ₹22 Cr | ₹20 Cr |
| ₹386 Cr | ₹13 Cr | ₹10 L | ₹3 Cr |
| ₹7 Cr | ₹3 Cr | ₹1 Cr | ₹1 L |
| ₹149 Cr | ₹85 Cr | ₹25 Cr | ₹1 Cr |
| ₹722 Cr | ₹251 Cr | ₹51 Cr | ₹27 Cr |
| ₹482 Cr | ₹3 Cr | -₹55 L | ₹17 Cr |
| ₹1208 Cr | ₹607 Cr | ₹131 Cr | ₹59 Cr |
| ₹171 | ₹67 | ₹46 | ₹42 |
| ₹171 | ₹67 | ₹46 | ₹42 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| ₹71 Cr | ₹25 Cr | ₹12 Cr | ₹1 Cr |
| ₹27 Cr | ₹18 Cr | ₹3 Cr | ₹1 Cr |
| -₹134 Cr | -₹66 Cr | -₹15 Cr | -₹13 Cr |
| -₹37 Cr | -₹23 Cr | ₹37 L | -₹10 Cr |
| -₹46 Cr | -₹26 Cr | -₹1 Cr | -₹10 Cr |
| -₹429 Cr | -₹54 Cr | -₹48 Cr | -₹24 Cr |
| ₹573 Cr | ₹87 Cr | ₹46 Cr | ₹36 Cr |
| ₹98 Cr | ₹7 Cr | -₹3 Cr | ₹2 Cr |
| ₹8 Cr | ₹10 L | ₹3 Cr | ₹2 Cr |
| ₹0 | ₹50 L | ₹0 | ₹0 |
| ₹105 Cr | ₹8 Cr | ₹10 L | ₹3 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found